Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 07, 2018

SELL
$73.28 - $102.95 $4,030 - $5,662
-55 Reduced 26.83%
150 $14,000
Q4 2017

Feb 08, 2018

BUY
$62.91 - $88.32 $7,549 - $10,598
120 Added 141.18%
205 $0
Q2 2017

Aug 07, 2017

BUY
N/A
85
85 $0

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Mufg Americas Holdings Corp Portfolio

Follow Mufg Americas Holdings Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Americas Holdings Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Americas Holdings Corp with notifications on news.